On August 21, 2018, Arterial Network was informed that Yasheng Pharmaceutical, a leading domestic innovative pharmaceutical company, had submitted a Hong Kong stock listing application on August 20. In the prospectus, Yasheng Pharmaceutical has not disclosed the specific amount of funds raised.
Yasheng Pharmaceutical is an innovative enterprise specializing in the research and development of original drugs. The company is based in China and faces the world. It is oriented to the demand for clinical drug use without medicine. The design and research and development have "First-in-Class" or "Best- The high-end original innovative drug of in-Class potential.
The company has a number of core rushes in the field of new innovative mechanisms for the development of innovative drugs, especially in the area of ​​protein-protein interaction target, and is currently a global leader. It is understood that the company has more than 100 invention patents at home and abroad.
Based on the free core technology, in just a few years, the company successfully completed the product layout of re-tumor, hepatitis B and aging-related diseases. Among them, there are 7 original innovative drugs that have entered the clinical development stage of China, the United States and Australia in the I-II phase, and a number of original drugs are in pre-clinical research or earlier research stages.
Image from Yasheng Pharmaceuticals official website
The achievements in the research and development of high-end international original innovative drugs have also enabled the company to gain the trust of professional venture capital institutions and industrial capital in the industry. In 2015, the company won a total of 96 million RMB A round of financing from Yuanhe Origin, Yuanming Capital, Yuansheng Venture Capital, etc.; then, at the end of 2016, it won a VC of only RMB 500 million. In the B round of financing, in 2018, the company won the RMB 1 billion C round of financing led by Yuanming Fangyuan Fund, and the estimated post-investment valuation reached 4 billion yuan.
The investment in capital has accelerated the development of Yasheng Pharmaceutical. In 2017, the company launched the location and construction of the global industrial base, marking the company's formal transition from a single research and development model to a development model integrating R&D, production and sales.
In 2016, Arterial Network had the opportunity to interview Yang Dajun, founder of Yasheng Pharmaceutical. At that time, Yasheng Pharmaceutical had just received an invitation from the JP Morgan Conference and was preparing for the roadshow. At the same time, Yang Dajun also revealed the company's intention to list in the US in the interview.
This year, the Hong Kong Stock Exchange has thrown an olive branch for a profitable biotechnology company, and then there is news that Yasheng Pharmaceutical intends to go public in Hong Kong. Going to the US or going to Hong Kong? Compared to this, many biotech companies are currently struggling. However, from the list of several companies that have already announced their listing in Hong Kong, although the current stock price of biotech companies listed in Hong Kong is not ideal, it seems to be the general trend in the “home door†listing.
Shaanxi Kang New Pharmaceutical co., Ltd. , https://www.apipepdites.com